{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:21:18Z","timestamp":1791062478597,"version":"4.1.0"},"reference-count":170,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1038\/s41584-023-01034-z","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T17:01:20Z","timestamp":1696611680000},"page":"724-737","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0684-9542","authenticated-orcid":false,"given":"Wilson","family":"Bautista-Molano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Fern\u00e1ndez-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6749-9921","authenticated-orcid":false,"given":"Mar\u00eda Lorena","family":"Brance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Gabriela","family":"\u00c1vila Pedretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Burgos-Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Corbacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4739-4698","authenticated-orcid":false,"given":"Vanesa Laura","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Francisco","family":"D\u00edaz Coto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4667-6784","authenticated-orcid":false,"given":"Enrique","family":"Giraldo Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6566-9280","authenticated-orcid":false,"given":"Gustavo","family":"Gomes Resende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Arturo","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-1110","authenticated-orcid":false,"given":"Marwin","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9577-3078","authenticated-orcid":false,"given":"Sebasti\u00e1n Eduardo","family":"Ib\u00e1\u00f1ez Vodnizza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0643-6337","authenticated-orcid":false,"given":"Edwin","family":"J\u00e1uregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Ocampo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9526-5527","authenticated-orcid":false,"given":"Daniel Ruben","family":"Palleiro Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pen\u00e9lope Esther","family":"Palominos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Pacheco Tena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Andr\u00e9s","family":"Quiceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina Mar\u00eda","family":"Saldarriaga-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6863-7559","authenticated-orcid":false,"given":"Fernando Andr\u00e9s","family":"Sommerfleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6832-3728","authenticated-orcid":false,"given":"Annelise","family":"Goecke Sariego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-4054","authenticated-orcid":false,"given":"Claudia","family":"Vera Barrezueta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Enrique","family":"Vega Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-0389","authenticated-orcid":false,"given":"Oscar","family":"Vega Hinojosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-1874","authenticated-orcid":false,"given":"Gustavo","family":"Citera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7340-7264","authenticated-orcid":false,"given":"Carlos","family":"Lozada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Percival D.","family":"Sampaio-Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7671-5748","authenticated-orcid":false,"given":"Emilce","family":"Schneeberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3143-1084","authenticated-orcid":false,"given":"Enrique R.","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"1034_CR1","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","volume":"80","author":"V Navarro-Comp\u00e1n","year":"2021","unstructured":"Navarro-Comp\u00e1n, V., Sepriano, A., El-Zorkany, B. & van der Heijde, D. Axial spondyloarthritis. Ann. Rheum. Dis. 80, 1511\u20131521 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. The development of the Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann. Rheum. Dis. 68, 777\u2013783 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR3","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s10067-016-3184-2","volume":"35","author":"W Bautista-Molano","year":"2016","unstructured":"Bautista-Molano, W. et al. Analysis and performance of various classification criteria sets in a Colombian cohort of patients with spondyloarthritis. Clin. Rheumatol. 35, 1759\u20131767 (2016).","journal-title":"Clin. Rheumatol."},{"key":"1034_CR4","doi-asserted-by":"publisher","first-page":"e001450","DOI":"10.1136\/rmdopen-2020-001450","volume":"7","author":"C L\u00f3pez-Medina","year":"2021","unstructured":"L\u00f3pez-Medina, C. et al. Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study. RMD Open. 7, e001450 (2021).","journal-title":"RMD Open."},{"key":"1034_CR5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.22831","volume":"68","author":"C Stolwijk","year":"2016","unstructured":"Stolwijk, C., van Onna, M., Boonen, A. & van Tubergen, A. Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care. Res. 68, 1320\u20131331 (2016).","journal-title":"Arthritis Care. Res."},{"key":"1034_CR6","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42358-020-00161-5","volume":"61","author":"G Citera","year":"2021","unstructured":"Citera, G. et al. Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis. Adv. Rheumatol. 61, 2 (2021).","journal-title":"Adv. Rheumatol."},{"key":"1034_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.semarthrit.2014.10.009","volume":"44","author":"A Boonen","year":"2015","unstructured":"Boonen, A. et al. The burden of non-radiographic axial spondyloarthritis. Semin. Arthritis Rheum. 44, 556\u2013562 (2015).","journal-title":"Semin. Arthritis Rheum."},{"key":"1034_CR8","doi-asserted-by":"publisher","first-page":"e001769","DOI":"10.1136\/rmdopen-2021-001769","volume":"7","author":"M Garrido-Cumbrera","year":"2021","unstructured":"Garrido-Cumbrera, M. et al. EMAS working group. Impact of axial spondyloarthritis on mental health in Europe: results from the EMAS study. RMD Open. 7, e001769 (2021).","journal-title":"RMD Open."},{"key":"1034_CR9","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1136\/annrheumdis-2015-208174","volume":"75","author":"A Molt\u00f3","year":"2016","unstructured":"Molt\u00f3, A. et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann. Rheum. Dis. 75, 1016\u20131023 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR10","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3899\/jrheum.170520","volume":"45","author":"W Bautista-Molano","year":"2018","unstructured":"Bautista-Molano, W. et al. Prevalence of comorbidities and risk factors for comorbidities in patients with spondyloarthritis in Latin America: a comparative study with the general population and data from the ASAS-COMOSPA study. J. Rheumatol. 45, 206\u2013212 (2018).","journal-title":"J. Rheumatol."},{"key":"1034_CR11","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1093\/rheumatology\/kez119","volume":"58","author":"SS Zhao","year":"2019","unstructured":"Zhao, S. S. et al. Comorbidity burden in axial spondyloarthritis: a cluster analysis. Rheumatology 58, 1746\u20131754 (2019).","journal-title":"Rheumatology"},{"key":"1034_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro, S. et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann. Rheum. 82, 19\u201334 (2023).","journal-title":"Ann. Rheum."},{"key":"1034_CR13","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.reuma.2019.03.010","volume":"17","author":"G Reyes-Cordero","year":"2021","unstructured":"Reyes-Cordero, G. et al. Recommendations of the Mexican College of Rheumatology for the management of spondyloarthritis. Reumatol. Clin. 17, 37\u201345 (2021).","journal-title":"Reumatol. Clin."},{"key":"1034_CR14","first-page":"60","volume":"21","author":"GG Resende","year":"2020","unstructured":"Resende, G. G. et al. The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis - 2019. Adv. Rheumatol. 21, 60 (2020). 19.","journal-title":"Adv. Rheumatol."},{"key":"1034_CR15","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3899\/jrheum.141001","volume":"42","author":"S Rohekar","year":"2015","unstructured":"Rohekar, S. et al. 2014 update of the Canadian Rheumatology Association\/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the management of spondyloarthritis. part II: specific management recommendations. J. Rheumatol. 42, 665\u2013681 (2015).","journal-title":"J. Rheumatol."},{"key":"1034_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.reuma.2021.09.003","volume":"18","author":"W Bautista-Molano","year":"2022","unstructured":"Bautista-Molano, W. et al. 2021 clinical practice guideline for the early detection, diagnosis, treatment, and monitoring of patients with axial spondyloarthritis. Colombian Association of Rheumatology. Reumatol. Clin. 18, 191\u2013199 (2022).","journal-title":"Reumatol. Clin."},{"key":"1034_CR17","first-page":"CD000125","volume":"24","author":"G Flodgren","year":"2019","unstructured":"Flodgren, G., O\u2019Brien, M. A., Parmelli, E. & Grimshaw, J. M. Local opinion leaders: effects on professional practice and healthcare outcomes. Cochrane Database Syst. Rev. 24, CD000125 (2019). 6.","journal-title":"Cochrane Database Syst. Rev."},{"key":"1034_CR18","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward, M. M. et al. 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis. research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care. Res. 71, 1285\u20131299 (2019).","journal-title":"Arthritis Care. Res."},{"key":"1034_CR19","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jclinepi.2016.09.009","volume":"81","author":"HJ Sch\u00fcnemann","year":"2017","unstructured":"Sch\u00fcnemann, H. J. et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J. Clin. Epidemiol. 81, 101\u2013110 (2017).","journal-title":"J. Clin. Epidemiol."},{"key":"1034_CR20","doi-asserted-by":"publisher","first-page":"i1152","DOI":"10.1136\/bmj.i1152","volume":"352","author":"MC Brouwers","year":"2016","unstructured":"Brouwers, M. C., Kerkvliet, K. & Spithoff, K., AGREE Next Steps Consortium. The AGREE reporting checklist: a tool to improve reporting of clinical practice guidelines. Br. Med. J. 352, i1152 (2016).","journal-title":"Br. Med. J."},{"key":"1034_CR21","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 25, 603\u2013605 (2010).","journal-title":"Eur. J. Epidemiol."},{"key":"1034_CR22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt, G. H. et al. Going from evidence to recommendations. Br. Med. J. 336, 1049\u20131051 (2008).","journal-title":"Br. Med. J."},{"key":"1034_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado, P. et al. Assessment of SpondyloArthritis international Society. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann. Rheum. Dis. 70, 47\u201353 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR24","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs, D. A., Nussenblatt, R. B. & Rosenbaum, J. T., Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am. J. Ophthalmol. 140, 509\u2013516 (2005).","journal-title":"Am. J. Ophthalmol."},{"key":"1034_CR25","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nrrheum.2017.187","volume":"13","author":"J Kalden","year":"2017","unstructured":"Kalden, J. & Schulze-Koops, H. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment. Nat. Rev. Rheumatol. 13, 707\u2013718 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1034_CR26","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1136\/annrheumdis-2020-219585","volume":"80","author":"A Molto","year":"2021","unstructured":"Molto, A. et al. Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial. Ann. Rheum. Dis. 80, 1436\u20131444 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR27","unstructured":"US National Library of Medicine. A study treating participants with early axial spondyloarthritis (axSpA) taking an intense treatment approach versus routine treatment (STRIKE). ClinicalTrials.gov Identifier: NCT02897115 (2019)."},{"key":"1034_CR28","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1136\/annrheumdis-2021-220603","volume":"80","author":"J Sieper","year":"2021","unstructured":"Sieper, J. & Poddubnyy, D. What is the optimal target for a T2T approach in axial spondyloarthritis? Ann. Rheum. Dis. 80, 1367\u20131369 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR29","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.rdc.2020.01.013","volume":"46","author":"RE van Bentum","year":"2020","unstructured":"van Bentum, R. E. & van der Horst-Bruinsma, I. E. Axial spondyloarthritis in the era of precision medicine. Rheum. Dis. Clin. N. Am. 46, 367\u2013378 (2020).","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"1034_CR30","first-page":"1805","volume":"33","author":"A Barkhuizen","year":"2006","unstructured":"Barkhuizen, A. et al. Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J. Rheumatol. 33, 1805\u20131812 (2006).","journal-title":"J. Rheumatol."},{"key":"1034_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/rheumatology\/kep393","volume":"49","author":"M Benhamou","year":"2010","unstructured":"Benhamou, M., Gossec, L. & Dougados, M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs\/coxibs\u2019 treatment effect on C-reactive protein. Rheumatology 49, 536\u2013541 (2010).","journal-title":"Rheumatology"},{"key":"1034_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K","volume":"44","author":"M Dougados","year":"2001","unstructured":"Dougados, M. et al. Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 44, 180\u2013185 (2001).","journal-title":"Arthritis Rheum."},{"key":"1034_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/rheumatology\/38.3.235","volume":"38","author":"M Dougados","year":"1999","unstructured":"Dougados, M. et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology 38, 235\u2013244 (1999).","journal-title":"Rheumatology"},{"key":"1034_CR34","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/art.20985","volume":"52","author":"D Van Der Heijde","year":"2005","unstructured":"Van Der Heijde, D. et al. Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum. 52, 1205\u20131215 (2005).","journal-title":"Arthritis Rheum."},{"key":"1034_CR35","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.intimp.2017.11.003","volume":"54","author":"MJ Fattahi","year":"2018","unstructured":"Fattahi, M. J. et al. Evaluation of the efficacy and safety of \u03b2-D-mannuronic acid in patients with ankylosing spondylitis: a 12-week randomized, placebo-controlled, phase I\/II clinical trial. Int. Immunopharmacol. 54, 112\u2013117 (2018).","journal-title":"Int. Immunopharmacol."},{"key":"1034_CR36","first-page":"3031","volume":"19","author":"M Fan","year":"2020","unstructured":"Fan, M. et al. Indirect comparison of NSAIDs for ankylosing spondylitis: network meta-analysis of randomized, double-blinded, controlled trials. Exp. Ther. Med. 19, 3031\u20133041 (2020).","journal-title":"Exp. Ther. Med."},{"key":"1034_CR37","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/ard.2007.075309","volume":"67","author":"J Sieper","year":"2008","unstructured":"Sieper, J. et al. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann. Rheum. Dis. 67, 323\u2013329 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR38","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1097\/00007611-197708000-00014","volume":"70","author":"HR Mena","year":"1977","unstructured":"Mena, H. R. & Good, A. E. Management of ankylosing spondylitis with flurbiprofen or indomethacin. South. Med. J. 70, 945\u2013947 (1977).","journal-title":"South. Med. J."},{"key":"1034_CR39","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1001\/jama.1979.03300170031022","volume":"242","author":"A Calin","year":"1979","unstructured":"Calin, A. & Britton, M. Sulindac in ankylosing spondylitis: double-blind evaluation of sulindac and indomethacin. J. Am. Med. Assoc. 242, 1885\u20131886 (1979).","journal-title":"J. Am. Med. Assoc."},{"key":"1034_CR40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/j.1742-1241.1981.tb08215.x","volume":"35","author":"OA Sydnes","year":"1981","unstructured":"Sydnes, O. A. Comparison of piroxicam with indomethacin in ankylosing spondylitis: a double-blind crossover trial. Br. J. Clin. Pract. 35, 40\u201344 (1981).","journal-title":"Br. J. Clin. Pract."},{"key":"1034_CR41","first-page":"23","volume":"11","author":"TG Palferman","year":"1991","unstructured":"Palferman, T. G. & Webley, M. A comparative study of nabumetone and indomethacin in ankylosing spondylitis. Eur. J. Rheumatol. Inflamm. 11, 23\u201329 (1991).","journal-title":"Eur. J. Rheumatol. Inflamm."},{"key":"1034_CR42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/0002-9343(86)90082-3","volume":"80","author":"JJ Calabro","year":"1986","unstructured":"Calabro, J. J. Efficacy of diclofenac in ankylosing spondylitis. Am. J. Med. 80, 58\u201363 (1986).","journal-title":"Am. J. Med."},{"key":"1034_CR43","first-page":"426","volume":"36","author":"H Tannenbaum","year":"1984","unstructured":"Tannenbaum, H., DeCoteau, W. E. & Esdaile, J. M. A double blind multicenter trial comparing piroxicam and indomethacin in ankylosing spondylitis with long-term follow-up. Curr. Ther. Res. Clin. Exp. 36, 426\u2013435 (1984).","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"1034_CR44","first-page":"660","volume":"33","author":"W Ebner","year":"1983","unstructured":"Ebner, W., Poal Ballarin, J. M. & Boussina, I. Meclofenamate sodium in the treatment of ankylosing spondylitis. Report of a European double-blind controlled multicenter study. Arzneimittelforschung 33, 660\u2013663 (1983).","journal-title":"Arzneimittelforschung"},{"key":"1034_CR45","first-page":"309","volume":"92","author":"HC Burry","year":"1980","unstructured":"Burry, H. C. & Siebers, R. A comparison of flurbiprofen with naproxen in ankylosing spondylitis. N. Z. Med. J. 92, 309\u2013311 (1980).","journal-title":"N. Z. Med. J."},{"key":"1034_CR46","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/BF02032359","volume":"5","author":"MJAM Franssen","year":"1986","unstructured":"Franssen, M. J. A. M., Gribnau, F. W. J. & Van De Putte, L. B. A. A comparison of diflunisal and phenylbutazone in the treatment of ankylosing spondylitis. Clin. Rheumatol. 5, 210\u2013220 (1986).","journal-title":"Clin. Rheumatol."},{"key":"1034_CR47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1093\/rheumatology\/19.4.260","volume":"19","author":"BP Wordsworth","year":"1980","unstructured":"Wordsworth, B. P., Ebringer, R. W., Coggins, E. & Smith, S. A double-blind cross-over trial of fenoprofen and phenylbutazone in ankylosing spondylitis. Rheumatology 19, 260\u2013263 (1980).","journal-title":"Rheumatology"},{"key":"1034_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/rheumatology\/19.3.189","volume":"19","author":"T Gibson","year":"1980","unstructured":"Gibson, T. & Laurent, R. Sulindac and indomethacin in the treatment of ankylosing spondylitis: a double-blind cross-over study. Rheumatology 19, 189\u2013192 (1980).","journal-title":"Rheumatology"},{"key":"1034_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/rheumatology\/19.2.122","volume":"19","author":"M Shipley","year":"1980","unstructured":"Shipley, M., Berry, H. & Bloom, B. A double-blind cross-over trial of indomethacin, fenoprofen and placebo in ankylosing spondylitis, with comments on patient assessment. Rheumatology 19, 122\u2013125 (1980).","journal-title":"Rheumatology"},{"key":"1034_CR50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/ard.33.2.129","volume":"33","author":"RD Sturrock","year":"1974","unstructured":"Sturrock, R. D. & Hart, F. D. Double blind crossover comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann. Rheum. Dis. 33, 129\u2013131 (1974).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR51","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/BF00607674","volume":"11","author":"HR Mena","year":"1977","unstructured":"Mena, H. R. & Willkens, R. F. Treatment of ankylosing spondylitis with flurbiprofen or phenylbutazone. Eur. J. Clin. Pharmacol. 11, 263\u2013266 (1977).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"1034_CR52","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/ard.37.5.436","volume":"37","author":"BM Ansell","year":"1978","unstructured":"Ansell, B. M. et al. A comparative study of Butacote and Naprosyn in ankylosing spondylitis. Ann. Rheum. Dis. 37, 436\u2013439 (1978).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR53","first-page":"22","volume":"10","author":"PA Bacon","year":"1990","unstructured":"Bacon, P. A. An overview of the efficacy of etodolac in arthritic disorders. Eur. J. Rheumatol. Inflamm. 10, 22\u201334 (1990).","journal-title":"Eur. J. Rheumatol. Inflamm."},{"key":"1034_CR54","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1001\/jama.1981.03320190026021","volume":"246","author":"C Wasner","year":"1981","unstructured":"Wasner, C. et al. Nonsteroidal anti-inflammatory agents in rheumatoid arthritis and ankylosing spondylitis. J. Am. Med. Assoc. 246, 2168\u20132172 (1981).","journal-title":"J. Am. Med. Assoc."},{"key":"1034_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-016-1275-5","volume":"17","author":"E Balazcs","year":"2016","unstructured":"Balazcs, E. et al. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskelet. Disord. 17, 426 (2016).","journal-title":"BMC Musculoskelet. Disord."},{"key":"1034_CR56","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.curtheres.2014.08.002","volume":"76","author":"F Huang","year":"2014","unstructured":"Huang, F. et al. Efficacy and safety of celecoxib in Chinese patients with ankylosing spondylitis: a 6-week randomized, double-blinded study with 6-week open-label extension treatment. Curr. Ther. Res. Clin. Exp. 76, 126\u2013133 (2014).","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"1034_CR57","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/0300060516628704","volume":"44","author":"C Walker","year":"2016","unstructured":"Walker, C., Essex, M. N., Li, C. & Park, P. W. Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients. J. Int. Med. Res. 44, 483\u2013495 (2016).","journal-title":"J. Int. Med. Res."},{"key":"1034_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1136\/ard.37.1.85","volume":"37","author":"F Van Gerwen","year":"1978","unstructured":"Van Gerwen, F., Van Der Korst, J. K. & Gribnau, F. W. J. Double blind trial of naproxen and phenylbutazone in ankylosing spondylitis. Ann. Rheum. Dis. 37, 85\u201388 (1978).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR59","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders, A. et al. Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 52, 1756\u20131765 (2005).","journal-title":"Arthritis Rheum."},{"key":"1034_CR60","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","volume":"71","author":"F Kroon","year":"2012","unstructured":"Kroon, F. et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann. Rheum. Dis. 71, 1623\u20131629 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR61","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","volume":"71","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy, D. et al. Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German spondyloarthritis inception cohort. Ann. Rheum. Dis. 71, 1616\u20131622 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR62","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper, J. et al. Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann. Rheum. Dis. 75, 1438\u20131443 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR63","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/rheumatology\/35.8.767","volume":"35","author":"Y Maugars","year":"1996","unstructured":"Maugars, Y., Mathis, C., Berthelot, J. M., Charlier, C. & Prost, A. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br. J. Rheumatol. 35, 767\u2013770 (1996).","journal-title":"Br. J. Rheumatol."},{"key":"1034_CR64","first-page":"88","volume":"17","author":"R Luukkainen","year":"1999","unstructured":"Luukkainen, R. et al. Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clin. Exp. Rheumatol. 17, 88\u201390 (1999).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1034_CR65","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00296-005-0008-0","volume":"26","author":"I G\u00fcnaydin","year":"2006","unstructured":"G\u00fcnaydin, I., Pereira, P. L., Fritz, J., K\u00f6nig, C. & K\u00f6tter, I. Magnetic resonance imaging guided corticosteroid injection of sacroiliac joints in patients with spondylarthropathy. Are multiple injections more beneficial? Rheumatol. Int. 26, 396\u2013400 (2006).","journal-title":"Rheumatol. Int."},{"key":"1034_CR66","first-page":"465","volume":"14","author":"A Migliore","year":"2010","unstructured":"Migliore, A. et al. A new technical contribution for ultrasound-guided injections of sacro-iliac joints. Eur. Rev. Med. Pharmacol. Sci. 14, 465\u2013469 (2010).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"1034_CR67","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1097\/RHU.0000000000001584","volume":"28","author":"B Nam","year":"2022","unstructured":"Nam, B. et al. Efficacy and safety of intra-articular sacroiliac glucocorticoid injections in ankylosing spondylitis. J. Clin. Rheumatol. 28, e26\u2013e32 (2022).","journal-title":"J. Clin. Rheumatol."},{"key":"1034_CR68","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1093\/rheumatology\/keab275","volume":"60","author":"V Dhir","year":"2021","unstructured":"Dhir, V., Mishra, D. & Samanta, J. Glucocorticoids in spondyloarthritis \u2014 systematic review and real-world analysis. Rheumatology 60, 4463\u20134475 (2021).","journal-title":"Rheumatology"},{"key":"1034_CR69","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/art.1780310905","volume":"31","author":"M Nissil\u00e4","year":"1988","unstructured":"Nissil\u00e4, M. et al. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum. 31, 1111\u20131116 (1988).","journal-title":"Arthritis Rheum."},{"key":"1034_CR70","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF02208032","volume":"10","author":"HG Taylor","year":"1991","unstructured":"Taylor, H. G., Beswick, E. J. & Dawes, P. T. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin. Rheumatol. 10, 43\u201348 (1991).","journal-title":"Clin. Rheumatol."},{"key":"1034_CR71","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/bmj.293.6552.911","volume":"293","author":"M Dougados","year":"1986","unstructured":"Dougados, M., Boumier, P. & Amor, B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br. Med. J. 293, 911\u2013914 (1986).","journal-title":"Br. Med. J."},{"key":"1034_CR72","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/rheumatology\/28.5.410","volume":"28","author":"MJ Davis","year":"1989","unstructured":"Davis, M. J., Dawes, P. T., Beswick, E., Lewin, I. V. & Stanworth, D. R. Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin a-alpha-1-antitrypsin. Rheumatology 28, 410\u2013413 (1989).","journal-title":"Rheumatology"},{"key":"1034_CR73","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/rheumatology\/29.1.41","volume":"29","author":"MM Corkill","year":"1990","unstructured":"Corkill, M. M., Jobanputra, P., Gibson, T. & Macfarlane, D. A controlled trial of sulphasalazine treatment of chronic ankylosing spondylitis: failure to demonstrate a clinical effect. Rheumatology 29, 41\u201345 (1990).","journal-title":"Rheumatology"},{"key":"1034_CR74","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/rheumatology\/32.8.729","volume":"32","author":"J Kirwan","year":"1993","unstructured":"Kirwan, J., Edwards, A., Huitfeldt, B., Thompson, P. & Currey, H. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Rheumatology 32, 729\u2013733 (1993).","journal-title":"Rheumatology"},{"key":"1034_CR75","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1002\/art.1780391209","volume":"39","author":"DO Clegg","year":"1996","unstructured":"Clegg, D. O. et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. Arthritis Rheum. 39, 1911\u20131912 (1996).","journal-title":"Arthritis Rheum."},{"key":"1034_CR76","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/ard.45.5.396","volume":"45","author":"N Feltelius","year":"1986","unstructured":"Feltelius, N. & Hallgren, R. Sulphasalazine in ankylosing spondylitis. Ann. Rheum. 45, 396\u2013399 (1986).","journal-title":"Ann. Rheum."},{"key":"1034_CR77","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/1756-185X.13124","volume":"21","author":"S Khanna Sharma","year":"2018","unstructured":"Khanna Sharma, S., Kadiyala, V., Naidu, G. & Dhir, V. A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. Int. J. Rheum. Dis. 21, 308 (2018).","journal-title":"Int. J. Rheum. Dis."},{"key":"1034_CR78","doi-asserted-by":"crossref","unstructured":"Venkatesh, S., Vishad, V., Viswanath, V., Deepak, T. & Mehtab, A. A prospective double blind placebo controlled trial of combination disease modifying antirheumatic drugs vs monotherapy (sulfasalazine) in patients with inflammatory low backache in ankylosing spondylitis and undifferentiated spondyloarthropathy. J. Arthritis S1 1041722167-7921S1-001 (2015).","DOI":"10.4172\/2167-7921.S1-001"},{"key":"1034_CR79","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/rheumatology\/41.11.1330","volume":"41","author":"B Roychowdhury","year":"2002","unstructured":"Roychowdhury, B. et al. Is methotrexate effective in ankylosing spondylitis? Rheumatology 41, 1330\u20131332 (2002).","journal-title":"Rheumatology"},{"key":"1034_CR80","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/030097401753180318","volume":"30","author":"L Altan","year":"2001","unstructured":"Altan, L. et al. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand. J. Rheumatol. 30, 255\u2013259 (2001).","journal-title":"Scand. J. Rheumatol."},{"key":"1034_CR81","first-page":"1568","volume":"31","author":"L Gonzalez-Lopez","year":"2004","unstructured":"Gonzalez-Lopez, L., Garcia-Gonzalez, A., Vazquez-Del-Mercado, M., Mu\u00f1oz-Valle, J. F. & Gamez-Nava, J. I. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J. Rheumatol. 31, 1568\u20131574 (2004).","journal-title":"J. Rheumatol."},{"key":"1034_CR82","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1136\/ard.2006.054098","volume":"66","author":"H Haibel","year":"2007","unstructured":"Haibel, H. et al. No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann. Rheum. Dis. 66, 419\u2013421 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR83","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1136\/ard.2005.036491","volume":"64","author":"JC Van Denderen","year":"2005","unstructured":"Van Denderen, J. C. et al. Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann. Rheum. Dis. 64, 1761\u20131764 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR84","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","volume":"79","author":"M Dougados","year":"2020","unstructured":"Dougados, M. & Wei, J. C. et al. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann. Rheum. Dis. 79, 176\u2013185 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR85","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3899\/jrheum.200093","volume":"48","author":"U Kiltz","year":"2021","unstructured":"Kiltz, U. & Wei, J. C. et al. Ixekizumab improves functioning and health in the treatment of radiographic axial spondyloarthritis: week 52 results from 2 pivotal studies. J. Rheumatol. 48, 188\u2013197 (2021).","journal-title":"J. Rheumatol."},{"key":"1034_CR86","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/cpt.1305","volume":"105","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. Model-based meta-analysis in ankylosing spondylitis: a quantitative comparison of biologics and small targeted molecules. Clin. Pharmacol. Ther. 105, 1244\u20131255 (2019).","journal-title":"Clin. Pharmacol. Ther."},{"key":"1034_CR87","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D Van Der Heijde","year":"2017","unstructured":"Van Der Heijde, D. et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann. Rheum. Dis. 76, 1340\u20131347 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR88","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar, A. et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann. Rheum. Dis. 80, 1004\u20131013 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR89","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","volume":"394","author":"DSI van der Heijde","year":"2019","unstructured":"van der Heijde, D. S. I. et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial. Lancet 394, 2108\u20132117 (2019).","journal-title":"Lancet"},{"key":"1034_CR90","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"DBX van der Heijde","year":"2018","unstructured":"van der Heijde, D. B. X. et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392, 2378\u20132387 (2018).","journal-title":"Lancet"},{"key":"1034_CR91","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg, S. R. et al. ORAL surveillance investigators. cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N. Engl. J. Med. 386, 316\u2013326 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1034_CR92","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/ar3350","volume":"13","author":"D Mulleman","year":"2011","unstructured":"Mulleman, D. et al. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res. Ther. 13, R82 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"1034_CR93","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/rheumatology\/ken207","volume":"47","author":"EK Li","year":"2008","unstructured":"Li, E. K. et al. Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology 47, 1358\u20131363 (2008).","journal-title":"Rheumatology"},{"key":"1034_CR94","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/art.39691","volume":"68","author":"MJ Nissen","year":"2016","unstructured":"Nissen, M. J. et al. The effect of comedication with a conventional synthetic disease-modifying antirheumatic drug on drug retention and clinical effectiveness of anti\u2013tumor necrosis factor therapy in patients with axial spondyloarthritis. Arthritis Rheumatol. 68, 2141\u20132150 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"1034_CR95","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jbspin.2006.08.005","volume":"74","author":"VC P\u00e9rez-Guijo","year":"2007","unstructured":"P\u00e9rez-Guijo, V. C. et al. Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74, 254\u2013258 (2007).","journal-title":"Joint Bone Spine"},{"key":"1034_CR96","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.1093\/rheumatology\/keac174","volume":"61","author":"M Nissen","year":"2022","unstructured":"Nissen, M. et al. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology 61, 4741\u20134751 (2022).","journal-title":"Rheumatology"},{"key":"1034_CR97","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","volume":"18","author":"W Park","year":"2016","unstructured":"Park, W. et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res. Ther. 18, 25 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"1034_CR98","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1016\/S2665-9913(19)30013-X","volume":"1","author":"H Xu","year":"2019","unstructured":"Xu, H. & Zhijun, L. et al. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial. Lancet Rheumatol. 1, e35 (2019).","journal-title":"Lancet Rheumatol."},{"key":"1034_CR99","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40259-020-00408-z","volume":"34","author":"J Su","year":"2020","unstructured":"Su, J. & Li, M. et al. Comparison of the efficacy and safety of adalimumab (Humira) and the adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis: a multicenter, randomized, double-blind, parallel, phase III clinical trial. BioDrugs 34, 381\u2013393 (2020).","journal-title":"BioDrugs"},{"key":"1034_CR100","doi-asserted-by":"publisher","first-page":"e001079","DOI":"10.1136\/rmdopen-2019-001079","volume":"5","author":"U Lindstr\u00f6m","year":"2019","unstructured":"Lindstr\u00f6m, U. et al. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics na\u00efve patients with spondyloarthritis. RMD Open\u00a05, e001079 (2019).","journal-title":"RMD Open"},{"key":"1034_CR101","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s10067-019-04496-3","volume":"38","author":"SC Kowalski","year":"2019","unstructured":"Kowalski, S. C. et al. PANLAR consensus statement on biosimilars. Clin. Rheumatol. 38, 1485\u20131496 (2019).","journal-title":"Clin. Rheumatol."},{"key":"1034_CR102","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","volume":"400","author":"A Deodhar","year":"2022","unstructured":"Deodhar, A. et al. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 400, 369\u2013379 (2022).","journal-title":"Lancet"},{"key":"1034_CR103","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13075-018-1610-3","volume":"20","author":"IB McInnes","year":"2018","unstructured":"McInnes, I. B. et al. FUTURE 2 Study Group. Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. Arthritis Res. Ther. 20, 113 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"1034_CR104","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.3899\/jrheum.160275","volume":"43","author":"A Kavanaugh","year":"2016","unstructured":"Kavanaugh, A. et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J. Rheumatol. 43, 1713\u20131717 (2016).","journal-title":"J. Rheumatol."},{"key":"1034_CR105","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1136\/ard.2006.052092","volume":"65","author":"S Guignard","year":"2006","unstructured":"Guignard, S. et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann. Rheum. Dis. 65, 1631\u20131634 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR106","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J Braun","year":"2005","unstructured":"Braun, J., Baraliakos, X., Listing, J. & Sieper, J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 52, 2447\u20132451 (2005).","journal-title":"Arthritis Rheum."},{"key":"1034_CR107","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/rheumatology\/ken091","volume":"47","author":"T Cobo-Ib\u00e1\u00f1ez","year":"2008","unstructured":"Cobo-Ib\u00e1\u00f1ez, T., del Carmen Ord\u00f3\u00f1ez, M., Mu\u00f1oz-Fern\u00e1ndez, S., Madero-Prado, R. & Mart\u00edn-Mola, E. Do TNF-blockers reduce or induce uveitis? Rheumatology 47, 731\u2013732 (2008).","journal-title":"Rheumatology"},{"key":"1034_CR108","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","volume":"48","author":"D Fouache","year":"2009","unstructured":"Fouache, D. et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology 48, 761\u2013764 (2009).","journal-title":"Rheumatology"},{"key":"1034_CR109","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/ard.2008.092585","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit, M. et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann. Rheum. Dis. 68, 696\u2013701 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR110","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.3346\/jkms.2019.34.e278","volume":"34","author":"S Lee","year":"2019","unstructured":"Lee, S., Park, Y. J. & Lee, J. Y. The effect of tumor necrosis factor-alpha inhibitors on uveitis in patients with ankylosing spondylitis. J. Korean Med. Sci. 34, e278 (2019).","journal-title":"J. Korean Med. Sci."},{"key":"1034_CR111","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","volume":"80","author":"U Lindstr\u00f6m","year":"2021","unstructured":"Lindstr\u00f6m, U. et al. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter? Ann. Rheum. Dis. 80, 1445\u20131452 (2021).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR112","doi-asserted-by":"publisher","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","volume":"68","author":"CA Lamb","year":"2019","unstructured":"Lamb, C. A. et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 68, s1\u2013s106 (2019).","journal-title":"Gut"},{"key":"1034_CR113","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/ajg.2009.727","volume":"105","author":"A Kornbluth","year":"2010","unstructured":"Kornbluth, A. & Sachar, D. B. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology practice parameters committee. Am. J. Gastroenterol. 105, 501\u2013523 (2010).","journal-title":"Am. J. Gastroenterol."},{"key":"1034_CR114","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ajg.2018.27","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein, G. R. et al. ACG clinical guideline: management of Crohn\u2019s disease in adults. Am. J. Gastroenterol. 113, 481\u2013517 (2018).","journal-title":"Am. J. Gastroenterol."},{"key":"1034_CR115","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","volume":"376","author":"Sandborn","year":"2017","unstructured":"Sandborn et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 376, 1723\u20131736 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1034_CR116","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"Hueber","year":"2012","unstructured":"Hueber et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693\u20131700 (2012).","journal-title":"Gut"},{"key":"1034_CR117","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s10067-018-4084-4","volume":"37","author":"X Chen","year":"2018","unstructured":"Chen, X., Zhang, T., Wang, W. & Xue, J. Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission. Clin. Rheumatol. 37, 1625\u20131632 (2018).","journal-title":"Clin. Rheumatol."},{"key":"1034_CR118","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1177\/0394632016656013","volume":"29","author":"J Li","year":"2016","unstructured":"Li, J. et al. Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population. Int. J. Immunopathol. Pharmacol. 29, 510\u2013515 (2016).","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"1034_CR119","first-page":"1","volume":"7","author":"F Cantini","year":"2013","unstructured":"Cantini, F., Niccoli, L., Cassar\u00e0, E., Kaloudi, O. & Nannini, C. Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study. Biol. Targets Ther. 7, 1\u20136 (2013).","journal-title":"Biol. Targets Ther."},{"key":"1034_CR120","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.3899\/jrheum.141335","volume":"42","author":"M Yates","year":"2015","unstructured":"Yates, M. et al. Is etanercept 25 mg once weekly as effective as 50 mg at maintaining response in patients with ankylosing spondylitis? A randomized control trial. J. Rheumatol. 42, 1175\u20131185 (2015).","journal-title":"J. Rheumatol."},{"key":"1034_CR121","first-page":"884","volume":"36","author":"F Lian","year":"2018","unstructured":"Lian, F. et al. Efficiency of dose reduction strategy of etanercept in patients with axial spondyloarthritis. Clin. Exp. Rheumatol. 36, 884\u2013890 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1034_CR122","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1002\/acr.24184","volume":"73","author":"DO Lawson","year":"2021","unstructured":"Lawson, D. O. et al. Tumor necrosis factor inhibitor dose reduction for axial spondyloarthritis: a systematic review and meta\u2010analysis of randomized controlled trials. Arthritis Care. Res. 73, 861\u2013872 (2021).","journal-title":"Arthritis Care. Res."},{"key":"1034_CR123","first-page":"174","volume":"33","author":"S Arends","year":"2015","unstructured":"Arends, S. et al. Patient-tailored dose reduction of TNF-\u03b1 blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin. Exp. Rheumatol. 33, 174\u2013180 (2015).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1034_CR124","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10067-007-0674-2","volume":"27","author":"S-H Lee","year":"2008","unstructured":"Lee, S.-H., Lee, Y.-A., Hong, S.-J. & Yang, H.-I. Etanercept 25 mg\/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin. Rheumatol. 27, 179\u2013181 (2008).","journal-title":"Clin. Rheumatol."},{"key":"1034_CR125","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00296-016-3428-0","volume":"36","author":"M Almirall","year":"2016","unstructured":"Almirall, M. et al. Drug levels, immunogenicity and assessment of active sacroiliitis in patients with axial spondyloarthritis under biologic tapering strategy. Rheumatol. Int. 36, 575\u2013578 (2016).","journal-title":"Rheumatol. Int."},{"key":"1034_CR126","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10067-013-2372-6","volume":"33","author":"R De Stefano","year":"2014","unstructured":"De Stefano, R., Frati, E., De Quattro, D., Menza, L. & Manganelli, S. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin. Rheumatol. 33, 707\u2013711 (2014).","journal-title":"Clin. Rheumatol."},{"key":"1034_CR127","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.3899\/jrheum.141128","volume":"42","author":"C Plasencia","year":"2015","unstructured":"Plasencia, C. et al. Comparing tapering strategy to standard dosing regimen of tumor necrosis factor inhibitors in patients with spondyloarthritis in low disease activity. J. Rheumatol. 42, 1638\u20131646 (2015).","journal-title":"J. Rheumatol."},{"key":"1034_CR128","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","volume":"75","author":"J Z\u00e1vada","year":"2016","unstructured":"Z\u00e1vada, J. et al. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann. Rheum. Dis. 75, 96\u2013102 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR129","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1007\/s10067-011-1722-5","volume":"30","author":"V Navarro-Comp\u00e1n","year":"2011","unstructured":"Navarro-Comp\u00e1n, V. et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin. Rheumatol. 30, 993\u2013996 (2011).","journal-title":"Clin. Rheumatol."},{"key":"1034_CR130","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s10067-010-1542-z","volume":"29","author":"J Lee","year":"2010","unstructured":"Lee, J. et al. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. Clin. Rheumatol. 29, 1149\u20131154 (2010).","journal-title":"Clin. Rheumatol."},{"key":"1034_CR131","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3899\/jrheum.111337","volume":"39","author":"J Paccou","year":"2012","unstructured":"Paccou, J., Bacl\u00e9-Boutry, M. A., Solau-Gervais, E., Bele-Philippe, P. & Flipo, R. M. Dosage adjustment of anti-tumor necrosis factor-\u03b1 inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J. Rheumatol. 39, 1418\u20131423 (2012).","journal-title":"J. Rheumatol."},{"key":"1034_CR132","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1093\/rheumatology\/kew269","volume":"55","author":"W Fong","year":"2016","unstructured":"Fong, W. et al. The effectiveness of a real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis. Rheumatology 55, 1837\u20131842 (2016).","journal-title":"Rheumatology"},{"key":"1034_CR133","doi-asserted-by":"publisher","first-page":"e0168958","DOI":"10.1371\/journal.pone.0168958","volume":"11","author":"JW Park","year":"2016","unstructured":"Park, J. W. et al. Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in ankylosing spondylitis. PLoS One 11, e0168958 (2016).","journal-title":"PLoS One"},{"key":"1034_CR134","doi-asserted-by":"publisher","first-page":"289845","DOI":"10.1155\/2013\/289845","volume":"2013","author":"B M\u00f6rck","year":"2013","unstructured":"M\u00f6rck, B., Pullerits, R., Geijer, M., Bremell, T. & Forsblad-d\u2019Elia, H. Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study. Mediators Inflamm. 2013, 289845 (2013).","journal-title":"Mediators Inflamm."},{"key":"1034_CR135","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10067-017-3965-2","volume":"37","author":"MH Chen","year":"2018","unstructured":"Chen, M. H. et al. Health-related quality of life outcomes in patients with rheumatoid arthritis and ankylosing spondylitis after tapering biologic treatment. Clin. Rheumatol. 37, 429\u2013438 (2018).","journal-title":"Clin. Rheumatol."},{"key":"1034_CR136","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","volume":"392","author":"R Landew\u00e9","year":"2018","unstructured":"Landew\u00e9, R. et al. Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study. Lancet 392, 134\u2013144 (2018).","journal-title":"Lancet"},{"key":"1034_CR137","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13075-019-1873-3","volume":"21","author":"M Moreno","year":"2019","unstructured":"Moreno, M. et al. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study. Arthritis Res. Ther. 21, 88 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1034_CR138","doi-asserted-by":"publisher","first-page":"R439","DOI":"10.1186\/ar1693","volume":"7","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos, X. et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res. Ther. 7, R439\u2013R444 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"1034_CR139","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-012-2571-5","volume":"33","author":"X Deng","year":"2013","unstructured":"Deng, X., Zhang, J., Zhang, J. & Huang, F. Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. Rheumatol. Int. 33, 1409\u20131413 (2013).","journal-title":"Rheumatol. Int."},{"key":"1034_CR140","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1093\/rheumatology\/41.11.1280","volume":"41","author":"M Breban","year":"2002","unstructured":"Breban, M. et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology 41, 1280\u20131285 (2002).","journal-title":"Rheumatology"},{"key":"1034_CR141","first-page":"672","volume":"29","author":"F Heldmann","year":"2011","unstructured":"Heldmann, F. et al. The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long-term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin. Exp. Rheumatol. 29, 672\u2013680 (2011).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1034_CR142","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s10067-017-3763-x","volume":"37","author":"M Zhao","year":"2018","unstructured":"Zhao, M. et al. Possible predictors for relapse from etanercept discontinuation in ankylosing spondylitis patients in remission: a three years\u2019 following-up study. Clin. Rheumatol. 37, 87\u201392 (2018).","journal-title":"Clin. Rheumatol."},{"key":"1034_CR143","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5114\/reum.2017.69775","volume":"55","author":"A Sebastian","year":"2017","unstructured":"Sebastian, A. et al. Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy. Reumatologia 55, 87\u201392 (2017).","journal-title":"Reumatologia"},{"key":"1034_CR144","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1002\/art.11017","volume":"48","author":"J Brandt","year":"2003","unstructured":"Brandt, J. et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 48, 1667\u20131675 (2003).","journal-title":"Arthritis Rheum."},{"key":"1034_CR145","doi-asserted-by":"publisher","first-page":"260","DOI":"10.2340\/16501977-1078","volume":"45","author":"I Kjeken","year":"2013","unstructured":"Kjeken, I. et al. A three-week multidisciplinary in-patient rehabilitation programme had positive long-term effects in patients with ankylosing spondylitis: randomized controlled trial. J. Rehabil. Med. 45, 260\u2013267 (2013).","journal-title":"J. Rehabil. Med."},{"key":"1034_CR146","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/rheumatology\/26.1.40","volume":"26","author":"SJ Bulstrode","year":"1987","unstructured":"Bulstrode, S. J., Barefoot, J., Harrison, R. A. & Clarke, A. K. The role of passive stretching in the treatment of ankylosing spondylitis. Rheumatology 26, 40\u201342 (1987).","journal-title":"Rheumatology"},{"key":"1034_CR147","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jbspin.2006.12.003","volume":"74","author":"F Cozzi","year":"2007","unstructured":"Cozzi, F. et al. Mud-bath treatment in spondylitis associated with inflammatory bowel disease \u2014 a pilot randomised clinical trial. Joint Bone Spine 74, 436\u2013439 (2007).","journal-title":"Joint Bone Spine"},{"key":"1034_CR148","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s002960100101","volume":"20","author":"JV Viitanen","year":"2001","unstructured":"Viitanen, J. V. & Heikkil\u00e4, S. Functional changes in patients with spondylarthropathy. A controlled trial of the effects of short-term rehabilitation and 3-year follow-up. Rheumatol. Int. 20, 211\u2013214 (2001).","journal-title":"Rheumatol. Int."},{"key":"1034_CR149","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1007\/s00296-011-1932-9","volume":"32","author":"L Altan","year":"2012","unstructured":"Altan, L., Korkmaz, N., Dizdar, M. & Yurtkuran, M. Effect of Pilates training on people with ankylosing spondylitis. Rheumatol. Int. 32, 2093\u20132099 (2012).","journal-title":"Rheumatol. Int."},{"key":"1034_CR150","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00296-008-0756-8","volume":"29","author":"D Durmus","year":"2009","unstructured":"Durmus, D., Alayli, G., Cil, E. & Canturk, F. Effects of a home-based exercise program on quality of life, fatigue, and depression in patients with ankylosing spondylitis. Rheumatol. Int. 29, 673\u2013677 (2009).","journal-title":"Rheumatol. Int."},{"key":"1034_CR151","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jbspin.2008.06.013","volume":"76","author":"D Durmu\u015f","year":"2009","unstructured":"Durmu\u015f, D. et al. Effects of two exercise interventions on pulmonary functions in the patients with ankylosing spondylitis. Joint Bone Spine 76, 150\u2013155 (2009).","journal-title":"Joint Bone Spine"},{"key":"1034_CR152","first-page":"739","volume":"31","author":"C Rodr\u00edguez-Lozano","year":"2013","unstructured":"Rodr\u00edguez-Lozano, C. et al. Outcome of an education and home-based exercise programme for patients with ankylosing spondylitis: a nationwide randomised study. Clin. Exp. Rheumatol. 31, 739\u2013748 (2013).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1034_CR153","first-page":"261","volume":"17","author":"G Kraag","year":"1990","unstructured":"Kraag, G., Stokes, B., Groh, J., Helewa, A. & Goldsmith, C. The effects of comprehensive home physiotherapy and supervision on patients with ankylosing spondylitis - a randomized controlled trial. J. Rheumatol. 17, 261\u2013263 (1990).","journal-title":"J. Rheumatol."},{"key":"1034_CR154","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/art.1780340624","volume":"34","author":"G Gemignani","year":"1991","unstructured":"Gemignani, G., Olivieri, I., Ruju, G. & Pasero, G. Transcutaneous electrical nerve stimulation in ankylosing spondylitis: a double-blind study. Arthritis Rheum. 34, 788\u2013789 (1991).","journal-title":"Arthritis Rheum."},{"key":"1034_CR155","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1093\/ptj\/86.7.924","volume":"86","author":"G Ince","year":"2006","unstructured":"Ince, G., Sarpel, T., Durgun, B. & Erdogan, S. Effects of a multimodal exercise program for people with ankylosing spondylitis. Phys. Ther. 86, 924\u2013935 (2006).","journal-title":"Phys. Ther."},{"key":"1034_CR156","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1002\/acr.22062","volume":"65","author":"K Niedermann","year":"2013","unstructured":"Niedermann, K. et al. Effect of cardiovascular training on fitness and perceived disease activity in people with ankylosing spondylitis. Arthritis Care Res. 65, 1844\u20131852 (2013).","journal-title":"Arthritis Care Res."},{"key":"1034_CR157","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/0269215508101748","volume":"23","author":"K Widberg","year":"2009","unstructured":"Widberg, K., Hossein, K. & Hafstr\u00f6m, I. Self- and manual mobilization improves spine mobility in men with ankylosing spondylitis \u2014 a randomized study. Clin. Rehabil. 23, 599\u2013608 (2009).","journal-title":"Clin. Rehabil."},{"key":"1034_CR158","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3899\/jrheum.100987","volume":"38","author":"S Masiero","year":"2011","unstructured":"Masiero, S. et al. Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy. A randomized controlled trial. J. Rheumatol. 38, 1335\u20131342 (2011).","journal-title":"J. Rheumatol."},{"key":"1034_CR159","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1177\/0269215513512214","volume":"28","author":"S Masiero","year":"2014","unstructured":"Masiero, S. et al. Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up. Clin. Rehabil. 28, 562\u2013572 (2014).","journal-title":"Clin. Rehabil."},{"key":"1034_CR160","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/014107680710000716","volume":"100","author":"E Ernst","year":"2007","unstructured":"Ernst, E. Adverse effects of spinal manipulation: a systematic review. J. R. Soc. Med. 100, 330\u2013338 (2007).","journal-title":"J. R. Soc. Med."},{"key":"1034_CR161","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jmpt.2013.05.009","volume":"38","author":"JJ Hebert","year":"2015","unstructured":"Hebert, J. J., Stomski, N. J., French, S. D. & Rubinstein, S. M. Serious adverse events and spinal manipulative therapy of the low back region: a systematic review of cases. J. Manipulative Physiol. Ther. 38, 677\u2013691 (2015).","journal-title":"J. Manipulative Physiol. Ther."},{"key":"1034_CR162","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.math.2009.12.006","volume":"15","author":"D Carnes","year":"2010","unstructured":"Carnes, D., Mars, T. S., Mullinger, B., Froud, R. & Underwood, M. Adverse events and manual therapy: a systematic review. Man. Ther. 15, 355\u2013363 (2010).","journal-title":"Man. Ther."},{"key":"1034_CR163","first-page":"223","volume":"13","author":"LA Rinsky","year":"1976","unstructured":"Rinsky, L. A., Reynolds, G. G., Jameson, R. M. & Hamilton, R. D. A cervical spinal cord injury following chiropractic manipulation. Paraplegia 13, 223\u2013227 (1976).","journal-title":"Paraplegia"},{"key":"1034_CR164","first-page":"E90","volume":"63","author":"CC Liao","year":"2007","unstructured":"Liao, C. C. & Chen, L. R. Anterior and posterior fixation of a cervical fracture induced by chiropractic spinal manipulation in ankylosing spondylitis: a case report. J. Trauma 63, E90\u2013E94 (2007).","journal-title":"J. Trauma"},{"key":"1034_CR165","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.semarthrit.2021.07.021","volume":"51","author":"V Navarro-Compan","year":"2021","unstructured":"Navarro-Compan, V. et al. The ASAS-OMERACT core domain set for axial spondyloarthritis. Semin. Arthritis Rheum. 51, 1342\u20131349 (2021).","journal-title":"Semin. Arthritis Rheum."},{"key":"1034_CR166","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3899\/jrheum.211075","volume":"49","author":"EE Schneeberger","year":"2022","unstructured":"Schneeberger E. E. et al. Simplified Ankylosing Spondylitis Disease Activity Score (SASDAS) versus ASDAS: a post hoc analysis of a randomized controlled trial. J. Rheumatol. 49, 1100\u20131108 (2022).","journal-title":"J. Rheumatol."},{"key":"1034_CR167","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/ard.2008.100503","volume":"68","author":"D Vosse","year":"2009","unstructured":"Vosse, D. et al. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann. Rheum. Dis. 68, 1839\u20131842 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"1034_CR168","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3899\/jrheum.100363","volume":"37","author":"RJ Weiss","year":"2010","unstructured":"Weiss, R. J., Wick, M. C., Ackermann, P. W. & Montgomery, S. M. Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases \u2014 a case-control study with 53,108 patients with fracture. J. Rheumatol. 37, 2247\u20132250 (2010).","journal-title":"J. Rheumatol."},{"key":"1034_CR169","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1097\/RHU.0000000000001951","volume":"29","author":"ML Brance","year":"2023","unstructured":"Brance, M. L. et al. Argentine guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis in postmenopausal women and men aged 50 years and older. J. Clin. Rheumatol. 29, e59\u2013e70 (2023).","journal-title":"J. Clin. Rheumatol."},{"key":"1034_CR170","doi-asserted-by":"crossref","unstructured":"Baraliakos, X. et al. Effect of secukinumab versus adalimumab biosimilar on radiographic progression in patients with radiographic axial spondyloarthritis: a randomized phase IIIb study [abstract]. Arthritis Rheumatol. 74, https:\/\/acrabstracts.org\/abstract\/effect-of-secukinumab-versus-adalimumab-biosimilar-on-radiographic-progression-in-patients-with-radiographic-axial-spondyloarthritis-a-randomized-phase-iiib-study\/ (accessed 10 June 2023).","DOI":"10.1136\/annrheumdis-2023-eular.301"}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01034-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01034-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01034-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T13:04:35Z","timestamp":1698066275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01034-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":170,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1034"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-01034-z","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]},"assertion":[{"value":"5 September 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.B.M. declares that he has been a speaker and\/or participated in Advisory Boards for AbbVie, Amgen, Biopas, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis and Pfizer. D.G.F.\u00c1. declares that he has been a speaker for AbbVie, Biopas, Bristol Myers Squibb, Janssen, Lilly, Pfizer and Roche, and that patent No. 13215332 has been granted in his name by the Superintendencia de Industria y Comercio de \u201cSimulador anat\u00f3mico de hallazgos semiol\u00f3gicos en enfermedades reum\u00e1ticas\u201d (Calificaci\u00f3n internacional de patentes: A61F 2\/58, effective from 9 November 2013 to 9 November 2023). M.G.\u00c1.P. declares that she has received funding from INDEX and Pfizer for conference attendance. M.G. declares that he has attended advisory board meetings, scientific consultancies and has obtained speaking fees for AbbVie, Novartis, UCB, Esaote SpA, Janssen, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer and Sanofi Aventis. E.G.H. declares that he has participated in Advisory Boards for Novartis. S.E.I.V. declares that he has participated in an Advisory Board and has been a speaker for AbbVie, Bristol Myers Squibb and Novartis. E.J. declares that he has received funding from AbbVie to attend academic events. V.O. declares that she was a speaker for AbbVie in 2020 in rheumatology and uveitis programs. P.E.P. declares that she has participated in Advisory Boards for Janssen; has received funding from AbbVie, Janssen, Novartis, Pfizer and Roche for conference attendance; and received financial support from AbbVie to complete a Master\u2019s degree in spondyloarthritis at Universidad Europea de Madrid. D.R.P.R. declares that he has received funding from Janssen and Novartis to attend academic events. G.A.Q. declares that his wife is Medical Director at Janssen Pharmaceuticals. F.A.S. declares that he has been a speaker for AbbVie, Janssen, Novartis, Lilly and Tecnofarma. C.V.B. declares that she has been a speaker for Bago, MSD, Janssen, Medicamenta, Novartis, Pfizer and Roche and has participated in randomized clinical trials sponsored by MSD and Eli Lilly. I.C. declares that she has participated in events and advisory board for AbbVie. V.L.C. declares that she has been a speaker and participated in academic events for AbbVie, Janssen and Novartis. A.G.S. declares that she has been a speaker for AbbVie, Biopas and Novartis; has received advisory board payments from Johnson & Johnson; is an AbbVie-funded Protocol Investigator and was a Pfizer-funded protocol investigator until 2021. G.G.R. declares that he has been a speaker and participated in Advisory Boards for AbbVie, Janssen, Eli Lilly and Novartis. L.M.S.R. declares that she has been a speaker for Amgen, Biopas, Boehringer, Bristol Myers Squibb, Genzyme, Janssen, Eli Lilly, Novartis, Pfizer, Roche and Sanofi. C.P.T. declares that he has received speaker fees from and\/or has participated in research protocols for AbbVie, Eli Lilly, Gilead, Janssen, UCB, Novartis and Pfizer. E.S. declares that she has participated in advisory boards, given conferences or received grants from AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, Novartis, Pfizer and Raffo. G.C. declares that he has participated in advisory boards, given conferences or received grants from AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Genzyme, Gema Biotech, Glaxo, Janssen, Pfizer, Raffo, Roche and Sandoz. P.D.S.B. declares that he has participated in advisory boards, given conferences or received grants from AbbVie, Boehringer Ingelheim, Celltrion, Eli Lilly, Glaxo SmithKline, Novartis, Pfizer, Sandoz and UCB. E.R.S. declares that he has participated in advisory boards, conferences or received grants from AbbVie, Amgen, Bristol Myers Squibb, Genzyme, Glaxo, Janssen, Lilly, Novartis, Pfizer, Roche, Sandoz, Sanofi and UCB. M.L.B., R.B.V., J.F.D.C., L.A.G., L.E.V.E. and O.V.H. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}